文献速递泌尿男性生殖肿瘤

阿比特龙治疗一周期后血浆肿瘤基因转换可优化mCRPC预后分层

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
PubMed 文献 · Ann Oncol · 2021-03-29

该研究基于多中心II期试验(NCT01867710)中151例未经化疗的转移性去势抵抗性前列腺癌(mCRPC)患者,对治疗前、治疗一周期后(C2D1)及进展时的血浆DNA进行靶向测序,发现血浆肿瘤DNA检测与较短的总生存(OS)和无进展生存(PFS)相关,且治疗前及C2D1存在TP53、RB1或PTEN基因改变的患者OS显著更短;而治疗前阳性转为不可测的患者生存与治疗前不可测者无差异。

要点

  • 血浆肿瘤DNA检测与mCRPC患者较短的OS(HR 2.89)和PFS(HR 2.05)相关。
  • 治疗前及C2D1同时存在TP53、RB1或PTEN改变者OS显著更短(HR分别为7.13、6.24、11.9)。
  • 治疗前阳性转为C2D1不可测者的生存与治疗前不可测者无显著差异(P=0.48、0.43、0.5)。

核心结论

  • 阿比特龙治疗一周期后血浆基因检测可优化预后分层,并可能早期提示治疗获益。

研究设计与样本

  • 多中心II期试验(NCT01867710)中151例未经化疗的mCRPC患者,采集治疗前(128例)、C2D1(134例)和进展时(49例)血浆DNA,进行定制靶向二代测序覆盖TP53、AR、RB1、PTEN等基因外显子,并检测1500个富集SNP的泛基因组区域以评估肿瘤DNA。

主要发现

  • 血浆肿瘤DNA检测与较短OS(HR 2.89,95%CI 1.77-4.73,P≤0.0001)和PFS(HR 2.05,95%CI 1.36-3.11,P<0.001)相关。
  • 治疗前及C2D1存在TP53、RB1或PTEN改变者OS显著短于两个时间点均无改变者(TP53:HR 7.13,95%CI 2.37-21.47,P<0.001;RB1:HR 6.24,95%CI 1.97-19.73,P=0.002;PTEN:HR 11.9,95%CI 3.6-39.34,P<0.001)。
  • 治疗前阳性转为C2D1不可测者与治疗前不可测者的生存无显著差异(P=0.48、P=0.43、P=0.5)。
  • 进展样本中,治疗前存在AR增益的9/49例均检测到AR增益,8/49例检测到新发AR体细胞点突变。

临床怎么用

  • 对于mCRPC患者,可在阿比特龙治疗一周期后复查血浆肿瘤DNA,结合治疗前结果动态评估预后。
  • 治疗前及治疗一周期后持续存在TP53、RB1或PTEN改变提示预后极差,或需更密切监测或强化治疗策略。

局限性

  • 研究为II期试验的生物标志物分析,样本量有限,需更大规模研究验证。
  • 进展样本量较小(49例),AR改变分析可能不全面。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma tumor DNA fraction is prognostic in metastatic cancers. This could improve risk stratification before commencing a new treatment. We hypothesized that a second sample collected after one cycle of treatment could refine outcome prediction of patients identified as poor prognosis based on plasma DNA collected pre-treatment. PATIENTS AND METHODS: Plasma DNA [128 pre-treatment, 134 cycle 2 day 1 (C2D1), and 49 progression] from 151 chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients in a phase II study of abiraterone acetate (NCT01867710) were subjected to custom targeted next-generation sequencing covering exons of these genes: TP53, AR, RB1, PTEN, PIK3CA, BRCA1, BRCA2, ATM, CDK12, CHEK2, FANCA HDAC2 and PALB2. We also captured 1500 pan-genome regions enriched for single nucleotide polymorphisms to allow detection of tumor DNA using the rolling B-allele method. We tested associations with overall survival (OS) and progression-free survival (PFS). RESULTS: Plasma tumor DNA detection was associated with shorter OS [hazard ratio (HR): 2.89, 95% confidence intervals (CI): 1.77-4.73, P ≤ 0.0001] and PFS (HR: 2.05; 95% CI: 1.36-3.11, P < 0.001). Using a multivariable model including plasma tumor DNA, patients who had a TP53, RB1 or PTEN gene alteration pre-treatment and at C2D1 had a significantly shorter OS than patients with no alteration at either time point (TP53: HR 7.13, 95% CI 2.37-21.47, P < 0.001; RB1: HR 6.24, 95% CI 1.97-19.73, P = 0.002; PTEN: HR 11.9, 95% CI 3.6-39.34, P < 0.001). Patients who were positive pre-treatment and converted to undetectable had no evidence of a difference in survival compared with those who were undetectable pre-treatment (P = 0.48, P = 0.43, P = 0.5, respectively). Progression samples harbored AR gain in all patients who had gain pre-treatment (9/49) and de novo AR somatic point mutations were detected in 8/49 patients. CONCLUSIONS: Plasma gene testing after one cycle treatment refines prognostication and could provide an early indication of treatment benefit.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Jayaram A, Wingate A, Wetterskog D, et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann Oncol. 2021. PMID: 33794293. doi:10.1016/j.annonc.2021.03.196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。